Creating a Better Pathologist
Cart 0

2020, October 14-16: Hematopathology Tasting Menu: A Sampling of Delightful Diagnostic Challenges

$1,349.00

October 14-16, 2020 - Palm Springs, California

18 CME
18 SAMs

Course Schedule     Faculty Biographies

The most recent (2016) WHO classification of hematologic neoplasms delineates specific diagnostic criteria for well-defined neoplastic entities. However, pathologists who diagnose bone marrow biopsies and lymphoid proliferations often face challenges that are not directly addressed by the WHO system or represent reactive conditions that may mimic hematologic malignancies. These include atypical morphologic features, unexpected immunostaining patterns, and discordant genetic features in neoplastic entities. Pathologists often have difficulties applying the WHO criteria if they are not fully concordant with the expected patterns and/or if they are relatively new entities with which pathologists may be unfamiliar. Moreover, there is inherent subjectivity in interpreting morphologic findings and even the results of ancillary testing. The literature contains reports about the intrinsic interobserver variability in making hematopathology diagnoses and pitfalls when applying established criteria. This course aims to bridge the practice gaps between the 'ideal world' WHO classification system and the 'real world' of hematopathology diagnosis by presenting challenging case examples. These cases will illustrate how to interpret correctly and apply morphologic criteria in diagnosing hematologic neoplasms (including newer entities), how to avoid diagnosing malignancy in benign mimics, and how appropriately to integrate the results of ancillary testing with the morphology, particularly when there are discordant or unexpected results. We will provide participants with guidelines on how practically to approach such cases and avoid misdiagnosis, thereby improving their performance in daily practice. The target audience is general pathologists who diagnose bone marrow and lymphoid lesions, practicing hematopathologists and hematopathology fellows.

COURSE OBJECTIVES

  • Use ancillary testing appropriately to diagnose lymphoid neoplasms correctly
  • Recognize reactive mimics of hematopoietic neoplasms
  • Use morphologic clues effectively to guide the workup of myeloid neoplasms
  • Apply current (2016) WHO Classification criteria to the diagnosis of hematologic neoplasms, emphasizing newer entities

COURSE DIRECTORS

  • Robert P. Hasserjian, MD 
    Massachusetts General Hospital, Harvard Medical School

FACULTY

  • Adam Bagg, MD
    University of Pennsylvania
  • Amy Chadburn, MD
    Weill Cornell Medical College
  • Laurence de Leval, MD, PhD
    University Hospital of Lausanne, Switzerland

CONTINUING MEDICAL EDUCATION AND CONTINUING CERTIFICATION

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 18 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Continuing Certification (CC). Physicians can earn a maximum of 18 SAM credit hours. 

PHOTO POLICY

USCAP records courses at the Interactive Learning Center for future educational purposes. By registering for this course, you consent that your likeness may be used by USCAP.

CANCELLATION POLICY

Cancellations will be assessed an administrative charge of 25% of the total registration fee. There will be no refunds for cancellations within 14 days of the event. The Academy is not responsible for travel expenses incurred as a result of an event cancellation.